We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Accept Cookies
Rituximab, a monoclonal antibody against CD20, is a component of standard therapy for systemic DLBCL (R-CHOP). Since most patients with PCNSL have CD20, rituximab may also play a role in the treatment of PCNSL. At the same time, intraventricular administration of rituximab has also been shown to be feasible and possibly active.
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy